A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
NCT04833582
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class
Conditions
Osteosarcoma
Interventions
DRUG:
Azenosertib
DRUG:
Gemcitabine
Sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc